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 16	
ABSTRACT 17	
Ochratoxin A (OTA) is a mycotoxin produced by secondary metabolism of several fungi 18	
belonging to the genera Aspergillus and Penicillium. OTA is potentially nephrotoxic, neurotoxic, 19	
immunotoxic and carcinogenic in several animal species and in humans. This toxin has been 20	
detected in several human food and animal feed. The aim of this study was to determine OTA in 21	
blood samples of healthy and affected by chronic kidney disease (CKD) dogs. CKD group showed 22	
higher incidence of OTA-positivity than healthy dogs (96% vs 56%) and a significantly higher 23	
median value of OTA plasma concentration (0.008 ng/ml vs 0.144 ng/ml). No significant 24	
correlation was observed between OTA levels and creatinine values in CKD dogs. This is first 25	
study regarding OTA detection in plasma samples of healthy and CKD dogs; the presence of this 26	
toxin is higher in nephropatic patients but is not yet clear, if it is correlated with progression of the 27	
disease. 28	
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Chronic kidney disease (CKD) is one of the most common kidney disease in dogs, and its 31	
etiology is not fully clarified; it seem correlated with some “risk factors”, such as immunomediated 32	
diseases, systemic or urinary tract infections, nephrolithiasis, drug or substance nephrotoxicity, 33	
systemic and glomerular hypertension, chronic hypoperfusion, amyloidosis and others [29]. Several 34	
well-known associations exist between CKD and both environmental agents and conditions, such as 35	
heavy metals, mycotoxins, industrial chemicals and infections. An environmental factor that may be 36	
associated with CKD in animals and human is Ochratoxin A (OTA). Ochratoxins are a group of 37	
secondary metabolites of the Aspergillus and Penicillium genera and contaminate cereals, coffee, 38	
dried fruit and other products. This group consists of OTA (Fig. 1), its methyl ester, its ethyl ester 39	
(Ochratoxin C), 4-hydroxyochratoxin A, Ochratoxin B with its methyl and ethyl esters and 40	
Ochratoxin α. OTA is the most prevalent and toxic of the ochratoxins. Initial symptoms of 41	
ochratoxicosis observed in all species include anorexia, polydipsia, polyuria and dehydration, and 42	
are associated with renal damage [32]. Upon absorption, OTAs enter the circulatory system, bind to 43	
serum proteins and accumulate in the kidneys, where they disrupt protein synthesis and other 44	
pathways in proximal tubular cells. This results in the degeneration of the proximal tubules and 45	
interstitial fibroses [32]. OTA is also known to bind with DNA molecules and induce renal tumors 46	
in animal models, although its carcinogenic mechanism remains controversial [8, 21]. IARC 47	
classified OTA as possible human carcinogen (Group 2B) [11]. Long-term exposure to OTA in 48	
humans has been implicated in balkan endemic nephropathy (BEN) and associated with urinary 49	
tract tumors, because of rather high OTA levels detected in food samples and in blood or urine from 50	
affected patients [1, 20, 28]. Pigs are the most sensitive farm animal species to the nephrotoxicity of 51	
OTA. Progressive nephropathy is seen in pigs at dietary concentrations of 1 mg/kg (equivalent to 40 52	
µg/kg p.c.) [4]. Dog appears to be a species that is particularly vulnerable to this mycotoxin, which 53	
is well known for its nephrotoxic and immunosuppressive effects [3]. For example, a daily dose of 54	
0.2 mg OTA/kg BW for 2 weeks or a single dose of 7.8 mg OTA/kg BW showed to be fatal to 55	
young beagle dogs [33, 34]. Clinical symptoms of the OTA poisoning included anorexia, weight 56	
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loss, vomiting, tenesmus, bloody diarrhea, increased body temperature, tonsillitis, dehydration and 57	
prostration. These findings were confirmed by another study in which dogs showed similar 58	
symptoms at OTA doses between 0.2 and 3.0 mg/kg BW [13-15]. It was reported that six dogs died 59	
in Germany in 1987, one in Scotland in 1991 and three in Korea in 2006 as a result of renal failure 60	
after consumption of feed containing OTA [9, 12, 17]. In the European Union, AFB1 is the only 61	
mycotoxin for which precise maximum limits have been established for complete and 62	
complementary feeding stuffs intended for animals [6]. With regard to the presence of other types 63	
of mycotoxins in products intended for animal feeding, including OTA, there are simple “guidance 64	
values” [7].  65	
Several papers have been published concerning the occurrence of OTA in pet food. Razzazi 66	
et al. [30], quantified this mycotoxin in 60% of pet food samples (a total of 10 dry and 30 wet 67	
foods, respectively) purchased in the Polish and Austrian markets, with analogous percentages of 68	
positivity in the two types of products (40% and 43%, respectively), albeit with different levels of 69	
contamination (in the range of 0.21-13.1 µg/kg and 0.22-0.8 µg/kg, in dry and wet pet foods, 70	
respectively). Other studies conducted in Europe have shown, in contrast, a more sporadic OTA 71	
contamination in the pet food samples examined, for the most part in rather modest concentrations, 72	
always lower than 5 µg/kg [18, 22]. In a study conducted on 40 dry and wet dog foods available in 73	
the Austrian and German markets, Songsermsakul et al. [31] observed a range of OTA 74	
contamination (from 7 to 40 µg/kg). More recently, Gazzotti et al. [10] quantified OTA in 81% of 75	
48 italian extruded pet food samples with mean concentration of 23.8 ± 9.9 µg/kg and 13.0 ± 9.7 76	
µg/kg for standard and premium types, respectively. All the above results are below the guidance 77	
level set by European Commission, 2006. 78	
The aim of the present study was to retrospectively assess the OTA plasmatic levels in 79	
healthy and CKD dogs. 80	
MATERIALS AND METHODS 81	
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Case selection review: records of client-owned dogs of different breeds, sex, age and weight 82	
referred to the Mario Modenato Veterinary Teaching Hospital for nephrological consultation 83	
between December 2011 and December 2013 were reviewed. Apparently healthy dogs had been 84	
referred to the nephrology service, because of previous episodes of polyuria and polydipsia or 85	
evaluation of overall renal function before minor surgery. For each dog, data regarding history, 86	
results of biochemical analyses and urinalysis, and ultrasonographic findings were collected from 87	
the medical record to confirm the diagnosis of chronic kidney disease or to include as healthy dog. 88	
At the time of the initial examination, the dog’s history was recorded and a complete clinical 89	
evaluation was performed; findings of that evaluation were included in the medical record. All dog 90	
owners were asked for informed consent so that serum and plasma samples could be stored for 91	
research purposes. 92	
Renal panel with complete blood count (CBC) (5ml of blood used) and complete urinalysis 93	
performed at the time of the initial examination were obtained from the medical record of each dog; 94	
variables of interest included plasma concentrations of creatinine and urea and serum 95	
concentrations of albumin and total protein. Inclusion criteria for dogs with CKD included 96	
documented history of chronic renal disease, ultrasonographic findings and laboratory test results, 97	
indicating stable CKD for at least 3 months.  98	
Exclusion criteria for dogs were considered a documented history of acute kidney injury 99	
(AKI), ultrasonographic findings or laboratory signs of AKI, and serum azotemia secondary to 100	
urinary obstruction or volume-responsive acute kidney injury. For dogs with CKD, the stage of 101	
disease was classified according to the 2011 IRIS guidelines on the basis of plasma creatinine 102	
concentration as follows: stage 1, < 1.4 mg/dl (< 123.7 µmol/l); stage 2, 1.4 to 2.0 mg/dl (123.7 to 103	
176.8 µmol/l); stage 3, 2.1 to 5.0 mg/dl (185.6 to 442 µmol/l); and stage 4, > 5.0 mg/dl (> 442 104	
µmol/l). Glomerular filtration rate was tested in each dog by means of an iohexol plasma clearance 105	
assay, and results were obtained from the medical record. In the present study, plasma iohexol 106	
clearance < 60 ml/min/m2 was considered to represent a decreased GFR [16, 25]. 107	
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High-performance liquid chromatography method 108	
OTA (from Aspergillus ochraceus) (M 403.8) reference standard was purchased from Sigma 109	
(Milan, Italy). The OTA standard was dissolved in a toluene-acetic acid mixture (99:1 %, v/v) to 110	
give a stock solution of 200 µg/ml which was stored at -20°C until use. Working solutions were 111	
prepared by diluting daily the stock solution with the mobile phase consisting of methanol-sodium 112	
phosphate buffer (pH 7.5) 50:50 % v/v. HPLC-grade water, methanol and acetonitrile were 113	
purchased from VWR (Milan, Italy). The chromatographic system consisted of Jasco 880 pump and 114	
Jasco 821 fluorescence detector (Jasco, Tokyo, Japan). JascoBorwin software was used for data 115	
processing. The excitation wavelength (λex) and emission wavelength (λem) were set at 380 and 116	
420 nm. The reversed-phase column was a Luna C18 ODS2, 3 µm, (4.6 x 150mm) (Phenomenex® 117	
Torrance, CA, USA). The column was kept at room temperature. The HPLC was operated with 118	
mobile phase system consisting of methanol-phosphate buffer solution pH 7.5 (0.03 M Na2HPO4, 119	
0.007M NaH2PO4) 50/50 % v/v at flow rate of 1 ml/min. The HPLC method was validated 120	
according to [2]: selectivity, linearity, limits of determination (LOD) and quantification (LOQ), 121	
repeatability and reproducibility were determined. Calibration curves were based on the analysis of 122	
triplicate standards solution at 7 concentration levels in matrix. Plasma samples spiked with OTA at 123	
0.025, 0.05, 0.1, 0.25, 0.5, 1 and 2 ng/ml were analyzed using extraction and HPLC method. The 124	
experiment was repeated 5 times. Taking into account concentration step, plasma spiked samples 125	
corresponded to OTA standard concentrations of 0.1, 0.2, 0.4, 1, 2, 4 and 8 ng/ml. The repeatability 126	
was tested by analyzing samples of plasma spiked with OTA at the levels of 0.05 ng/ml 127	
(corresponding to 0.2 ng/ml), 0.25 ng/ml (corresponding to 1 ng/ml) and 2 ng/ml (corresponding to 128	
8 ng/ml). All samples were measured in triplicates on the same day. For the within-laboratory 129	
reproducibility test, each of the contamination level was tested in triplicates in seven days. The 130	
results of these experiments were used also for the determination of the recovery. Selectivity studies 131	
have been expressed as the ability to assess unequivocally OTA in the presence of components 132	
which may be expected to be present: it has been evaluated by the comparison of free-OTA vs 133	
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spiked samples. 134	
Samples preparation 135	
OTA was extracted according to [24]. One ml of plasma was mixed with 5 ml of MgCl2 (0.1 136	
M)-HCl (0.05 M) pH 1.5 solution and 5 ml of ethylacetate, vortexed for 1 min, shaked for 10 min 137	
on horizontal shaker, and then centrifuged for 10 min at 3,000 rpm. The organic phase was 138	
removed, the residue was re-extracted, with 5 ml of ethylacetate, and the organic phases were 139	
combined. Ethylacetate was evaporated to dryness under nitrogen stream and reconstituted in 250 µl 140	
of mobile phase and a 100 µl aliquote was injected into HPLC system. 141	
OTA confirmation 142	
For OTA positive samples, confirmation was done by OTA methyl ester formation. One 143	
hundred µl of mobile phase reconstituted sample were mixed with 300 µl of BF3 solution and the 144	
mixture was heated at 70 °C for 20 min; 50 µl of the mixture was then assayed for OTA-Me. 145	
Confirmation was based on the disappearance of the OTA peak, and the appearance of a peak 146	
corresponding to the OTA-Me. 147	
Statistical analysis 148	
Statistical analysis was performed with a standard software program. All data were tested 149	
for normality by means of the Kolmogorov- Smirnov test. The data are reported as mean and 150	
standard deviation. A value of p < 0.05 was considered significant. Variance analysis among mean 151	
values of OTA in healthy dogs and in dogs with IRIS stage 1, 2, 3 or 4 disease was performed by 152	
means of a ANOVA test followed by a Dunn multiple comparison test. Linear regression analysis 153	
and Spearman correlation coefficient analysis were used to assess the correlation of plasma 154	
creatinine and urea concentration and OTA levels for dogs at each stage of the IRIS classification. 155	
  156	
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 157	
RESULTS 158	
High-performance liquid chromatography method 159	
The calibration curve was established in the range of 0.025 to 2 ng/ml (r = 0.995). Limit of 160	
detection was equivalent to 0.0125 ng/ml. Average recovery was 81.9 ± 3.2%, 89.7 ± 0.8% and 161	
82.3 ± 1.5% respectively, in plasma samples enriched with OTA at the levels of 0.05, 0.25 and 2 162	
ng/ml (Table 1). All results were corrected for recovery. Each positive sample was confirmed by the 163	
OTA methyl ester formation, that showed disappearance of the OTA peak (retention time: 8.5 min) 164	
(Fig. 2) and appearance of the OA methyl ester peak (retention time: 14 min). 165	
Case classification  166	
Of 102 dogs referred for nephrological consultation between December 2010 and December 167	
2013, 46 were included in the study. 18 dogs of these had definitive diagnosis of CKD on the basis 168	
of azotemia, low urine specific gravity, renal proteinuria (urinary protein-creatinine concentration 169	
ratio, > 0.5) and abnormal renal morphology at ultrasonographic examination.  170	
All 18 dogs were classificated and divided in different stages of kidney disease (according to 171	
IRIS guidelines) as follows: stage 2, 5 dogs; stage 3, 6 dogs; and stage 4, 7 dogs.  172	
In other 28 dogs, no abnormalities were detected by CBC, biochemical analyses, urinalysis 173	
or ultrasonography, although some dogs had history of previous episodes of polyuria and 174	
polydipsia. However, for purposes of the present study, plasma iohexol clearance < 60 ml/min/m2 175	
was GFR assessments and 5 of these 28 apparently healthy dogs were considered to have early 176	
CKD and were classified as IRIS stage 1 (plasma creatinine concentration < 1.4 mg/dl [123.7 177	
µmol/l]). Twenty-three dogs were considered healthy and used as controls. 178	
All dogs with stage 2, 3 or 4 disease received specific treatment for chronic kidney disease 179	
(antacids, antiemetics, vitamin B complex and renal diet) according to the severity of clinical signs. 180	
The most common clinical signs were polyuria, polydipsia, weakness, dysorexia and vomiting. 181	
Polyuria, polydipsia and weakness were present in all dogs with stage 2 CKD and only 1 dog had 182	
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gastrointestinal signs.  183	
OTA concentrations 184	
Data regarding plasma OTA concentration were tested for normality (Kolmogorov-Smirnov 185	
test) and did not follow a Gaussian distribution. Rates of OTA-positive samples, median values and 186	
ranges of OTA plasma concentrations are given in Table 2. The CKD group exhibited both a 187	
significantly (p < 0.01) higher incidence of OTA-positivity than healthy subjects (96% vs 56%) and 188	
a significantly (p < 0.001) higher median values of plasma concentrations (0.008 ng/ml vs 0.144 189	
mg/ml). The highest OTA plasma concentration is observed in a CKD dog (1.05 ng/ml, i.e. 130-190	
fold the median value in healthy group).  191	
Rates of OTA-positive samples, median values and ranges of OTA plasma concentrations 192	
for healthy dogs and dogs with stage 1, 2, 3 and 4 are given in Table 2. The median OTA for 193	
healthy dogs and dogs with stage 1, 2, 3 and 4 disease differed significantly (Kruskal-Wallis test; p 194	
= 0.0002). Results of a Dunn post test indicated that there was a significant (p < 0.01) difference in 195	
OTA levels between healthy dogs and dogs with IRIS stage 1 disease and between healthy dogs and 196	
dogs with stage 4 disease, but not between healthy dogs and dogs with stage 2 or 3 disease dogs (p 197	
> 0.05) (Fig. 3). 198	
Spearman tests revealed no significant correlation between plasma OTA and both creatinine 199	
(p = 0.20) and urea (p = 0.11) plasma concentrations in healthy and CKD dogs (Fig. 4).  200	
  201	
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DISCUSSION 202	
Mycotoxins and related pathologies have become a worldwide issue and raise serious 203	
sanitary problems. Studies from several countries have attempted to investigate human exposure to 204	
OTA. Two approaches were undertaken: the analysis of food and the measurement of OTA in 205	
biological fluids. The later was used to evaluate association of human exposure to OTA and 206	
existence of human diseases, especially nephropathy [5, 19, 26]. The significance of OTA levels in 207	
human plasma as a marker of OTA intake can however be questioned. Although Szczech et al. [32, 208	
33] and Jeong et al. [12] have highlighted how the OTA exposure in dogs can result in serious 209	
kidney damage, to the author’s knowledge, this is the first study regarding OTA determination in 210	
plasma of dogs with different stages of CKD. In the present study, CKD patients showed both 211	
higher rates of OTA positivity and median values than the healthy population. Özçelik et al. [26] 212	
analyzed human plasma samples obtained from patients with different diseases of the urinary tract 213	
(CKD, bladder tumors and urinary) and from healthy controls. A statistically significant difference 214	
between the values of OTA present in the healthy and the sick ones was observed, with particular 215	
reference to CKD patients. The values of OTA detected in the blood of sick human patients, as well 216	
as those of healthy patients, are comparable with the values that we found in our study in the 217	
respective groups of dogs. The present results indicate the potentially contamination of food for 218	
animals with this toxin. OTA is a contaminant found not only in vegetable foods, but also in 219	
matrices of animal origin, as a result of the accumulation of these compounds in muscles, organs 220	
and offal (kidneys and liver, in particular), which are often used in high quantities by the pet food 221	
industry, especially for the formulation of wet products [23, 27]. The results obtained in this study 222	
suggest that OTA can have a role in the onset of kidney disease in dogs and the statistically 223	
significant difference between patients with CKD and healthy can be attributed to decreased 224	
glomerular filtration which increases the half-life of this toxin and could exacerbates its own 225	
toxicity.  226	
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In our study, OTA plasma concentration didn’t correlate with serum creatinine and urea. 227	
Furthermore, a statistically significant difference between healthy and dogs at stage 1 and stage 4 of 228	
kidney disease was observed, while no difference was observed between healthy and dogs with 229	
stages 2 and 3. These results may be explained, because of the high variability in median OTA 230	
concentration in groups 2 and 3 and also because of the small number of patients in each group.  231	
Biomonitoring is usually used to assess internal OTA exposure resulting from dietary intake 232	
and from other sources. Mycotoxin levels in blood and/or urine provide good estimates of past and 233	
recent exposure, since OTA binds to serum proteins and is also partly excreted via the kidney. But, 234	
measuring OTA alone does not reflect its biotransformation. The metabolism of OTA in animals 235	
and humans remains to be further investigated. Metabolism of OTA in rodents, especially in rats, 236	
was extensively investigated. However, the information in other species is not enough, especially 237	
for companion animals as dogs. Currently, no report on metabolism of OTA in dogs is available. 238	
Further studies should be carried out to understand its metabolism in companion animals. 239	
Our results show that OTA is detected in almost all plasma samples tested and suggest that 240	
OTA contamination is widespread in foods consumed by these animals. For these reasons, regular 241	
controls should be enforced and exposure to OTA should be kept to a minimum, avoiding the 242	
consumption of heavily contaminated foods. From an epidemiological point of view, OTA plasma 243	
levels are considered a short-term biomarker with a high within-subject variability; therefore, they 244	
have limited use at the individual level. However, OTA measurements can be used to characterize 245	
populations or subgroups of subjects, particularly in prospective studies storing plasma samples 246	
taken at baseline, well before possibly related outcomes occur. Additional studies of dietary 247	
determinants of OTA intake in animals are needed and the correlation between OTA levels and the 248	
consumption of specific food should be explored. 249	
 250	
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 352	
Figure legend: 353	
Fig. 1. Chemical structure of OTA. 354	
Fig. 2. Chromatogram of a OTA naturally-contaminated serum sample of a CKD dog (line A) and 355	
OTA standard dilution (10 ng/ml in HPLC mobile phase) (line B).  356	
Fig. 3. Concentrations of OTA in canine plasma of healthy dogs and IRIS stages 1, 2, 3 and 4 CKD 357	
dogs; Different letters (a, b) are used to report statistically significant differences (p < 0.05). 358	
Fig. 4. Spearman correlation analysis between plasma creatinine (mg/dl) and urea (mg/dl) and 359	
serum OTA levels (ng/ml) in healthy and CKD dogs. 360	
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Table 1. Validation parameters for HPLC method of OTA in canine plasma samples. 362	
Parameters  
LOD 0.0125 ng/ml 
LOQ 0.0250 ng/ml 
r2 0.995 (n = 5 replicates) 
CV % (intra-day)  
0.05 5.8 (n = 3 replicates) 
0.25 8.9 (n = 3 replicates) 
2.00 4.3 (n = 3 replicates) 
CV % (inter-day)  
0.05 9.7 (n = 21 replicates) 
0.25 8.3 (n = 21 replicates) 
2.00 7.0 (n = 21 replicates) 
Recovery %  
0.05 81.9 ± 3.2 (n = 21 replicates) 
0.25 89.7 ± 0.8 (n = 21 replicates) 
2.00 82.3 ± 1.5 (n = 21 replicates) 
LOD: limit of detection; LOQ: limit of quantification; CV: coefficient of variation. 363	
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Table 2. Concentrations of OTA in plasma of healthy, CKD and IRIS stages 1, 2, 3 and 4 365	
dogs. 366	
Group N. Median (range) ng/ml % of positives 
Healthy 23 0.008 (<LOD-0.27) 56% (13 of 23) 
CKD 23 0.144 (<LOD-1.05) 96% (22 of 23) 
    
IRIS stage 1 5 0.580 (0.007-1.050) 100% (5 of 5) 
IRIS stage 2 5 0.050 (<LOD-0.686) 80% (4 of 5) 
IRIS stage 3 6 0.101 (0.031-0.683) 100% (6 of 6) 
IRIS stage 4 7 0.221 (0.061-0.725) 100% (7 of 7) 
	367	
  368	
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Fig.	2	375	
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Fig.	4	383	
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